Dose-ranging study aims to identify optimal recombinant human IGF-I for pediatric hyperinsulinism

Hyperinsulinism (HI) is a rare genetic disorder causing excessive insulin secretion, leading to severe and persistent hypoglycemia. This can result in irreversible brain damage if not managed aggressively. Current treatments often involve frequent glucose infusions, medications like diazoxide or octreotide, or even pancreatectomy, all with significant side effects and varying efficacy. Insulin-like Growth Factor I (IGF-I) is a hormone with insulin-like metabolic effects, but it primarily acts via the IGF-1R and has a different receptor binding profile than insulin. Its potential to stabilize glucose levels by counteracting insulin's effects or providing alternative glucose utilization pathways makes it a candidate for managing HI, addressing the critical need for safer, more effective therapeutic options.

This was a short-term, dose-ranging study (NCT00004825) involving 10 children diagnosed with hyperinsulinism. The primary objective was to determine a dose of recombinant human insulin-like growth factor I (rhIGF-I) that could minimize or decrease the requirement for exogenous glucose support. The study also aimed to ensure that the administered dose did not induce hypoglycemia, a critical safety endpoint in this vulnerable population. Specific dosing regimens (e.g., mg/kg, route, frequency) were not detailed in the provided abstract, but the design implies a titration or escalating dose approach to identify an optimal therapeutic window.